Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …

Immune checkpoint therapy in breast cancer remains restricted to triple negative patients,
and long-term clinical benefit is rare. The primary aim of immune checkpoint blockade is to …

Purpose Programmed death receptor ligand-1 (PD-L1) expression and tumor mutational
burden (TMB) are approved screening biomarkers for immune checkpoint inhibition (ICI) in …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

We examined a large dataset of female metastatic breast cancers (MBCs) profiled with
comprehensive genomic profiling (CGP) to identify the prevalence and distribution of …

As an emerging antitumor strategy, immune checkpoint therapy is one of the most promising
anticancer therapies due to its long response duration. Antibodies against the programmed …

Background: The development of novel chemotherapeutic agents has significantly improved
the prognosis and survival of patients with breast cancer. ER positive or luminal tumors …

Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies
have already been studied in many clinical trials on various tumor types. In recent years, a …

Purpose Breast cancer has become the leading cause of cancer mortality in women.
Although immune checkpoint inhibitors targeting programmed death-1 (PD-1) are promising …

e15262 Background: The clinical benefit of immune checkpoint inhibitors (ICIs) targeting the
programmed death-1/programmed death ligand 1 (PD-L1) pathway has previously been …